

Learner Notification

Kneed Communications

Advancing the Diagnostic-to-Treatment Continuum in Hematologic Malignancies

August 13, 2026 - August 14, 2026

Irvine, CA

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of 7.00 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 7.00 knowledge-based CPE contact hours.

UAN JA4008163-9999-26-203-L01-P

NOTE to Pharmacists: *The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.*

Nurses

Amedco LLC designates this activity for a maximum of 7.00 ANCC contact hours.

American Board of Pathology (ABPath) MOC

This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 7.00 credit hours.

You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate current and emerging treatment strategies across hematologic malignancies, including myeloid neoplasms, acute leukemias, plasma cell disorders, CLL, and lymphomas.
2. Apply multidisciplinary, evidence-based approaches to therapeutic sequencing, transplant referral, toxicity management, and the integration of novel therapies, including CAR-T cell therapy and bispecific antibodies, into patient care.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Ibrahim Aldoss	AstraZeneca , Amgen, Pfizer , Autolus, KiTE, Adaptive, Acentage :Scientific/Medical Advisory Board Member AbbVie, Novartis:Research Grant Site Principal Investigator JAZZ:Research Grant Overall Principal Investigator
Haris Ali	incyte, pharmaessentia, GSK, Sobi:Speakers Bureau karyopharm, Takeda:Scientific/Medical Advisory Board Member incyte:Research Grant Site Principal Investigator
Jennifer Hanle	Pfizer, Sanofi:Speakers Bureau
Ben Heyman	Abbvie, Guardant:Consultant SOBI, Lilly, Regeneron :Scientific/Medical Advisory Board Member Incyte:Research Grant Overall Principal Investigator Astrazeneca, BeOne:Research Grant Site Principal Investigator
Murali Janakiram	Jannsen, BMS, Legend:Consultant Jannsen, BMS:Research Grant Site Principal Investigator
Autumn Jeong	Pfizer:Research Grant Overall Principal Investigator
Lisa Lee	NA
Howard McLeod	NA
Matthew Mei	BMS, Genentech, Incyte, BeOne, Merck:Research Grant Overall Principal Investigator
Ryotaro Nakamura	Ono Pharmaceuticals, Orca Bio, Sanofi:Consultant Miyarisan:Research Grant Overall Principal Investigator Omeros:Research Grant Site Principal Investigator
Casey O'Connell	Geron, Taiho:Scientific/Medical Advisory Board Member Taiho:Research Grant Site Principal Investigator
Tamer Othman	NA
David Oveisi	Johnson & Johnson:Research Grant Site Principal Investigator Johnson & Johnson:Speakers Bureau Johnson & Johnson, Bristol Meyers Squibb, Pfizer:Scientific/Medical Advisory Board Member
Deanna Russell	NA
Nigel Russell	NA
Geoffrey Shouse	ADC Therapeutics, BMS, BeOne Medicines, AstraZeneca, Marker Therapeutics, Kite Pharma, Merck:Consultant ADC Therapeutics, Kite Pharma, BeOne Medicines:Speakers Bureau

Tanya Siddiqi	Astra Zeneca, BeOne, BMS, Merck, Gilead, Pfizer:Scientific/Medical Advisory Board Member BMS:Research Grant Overall Principal Investigator
Swetha Thiruvengadam	ADC Therapeutics, Genentech, Genmab:Research Grant Overall Principal Investigator Incyte, Kite, Ipsen:Scientific/Medical Advisory Board Member
Jonathan Zuckerman	Amgen Inc, Appellis Pharmaceuticles, Vera therapeutics:Consultant
Naomi Terlouw	NA

How to Get Your Certificate

1. Go to kc.cmecertificateonline.com
 2. Click on the **2026 Advancing the Diagnostic-to-Treatment Continuum in Hematologic Malignancies** link.
 3. Evaluate the meeting.
 4. Print, download, or save your certificate for your records.
 5. If you lose your certificate, or need help, go to help.cmecertificateonline.com
-